Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - voriconazole -

New Zealand - English - Medsafe (Medicines Safety Authority)

neo health (nz) limited - voriconazole 200mg - powder for injection - 200 mg - active: voriconazole 200mg excipient: hydrochloric acid hydroxypropyl-beta-cyclodextrin sodium chloride water for injection - voriconazole is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - voriconazole -

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - voriconazole, quantity: 200 mg - injection, powder for - excipient ingredients: nitrogen; water for injections; sulfobutyl betadex sodium - voriconazole ? aft is indicated for treatment of the following fungal infections:,invasive aspergillosis.,serious candida infections (including c. krusei), including systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,serious fungal infections caused by scedosporium spp and fusarium spp.,other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - voriconazole 200mg - powder for injection - 200 mg - active: voriconazole 200mg excipient: sulfobutyl betadex sodium water for injection - voriconazole - aft is indicated for the following fungal infections: invasive aspergillosis serious candida infections (including c. krusei), including systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia) serious fungal infections caused by scedosporium spp and fusarium spp other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluconazole -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - allopurinol -

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - peginterferon alfa-2a 270 µg/ml; ribavirin 200mg;  ;   - combination - 135µg/0.5ml + 200mg - active: peginterferon alfa-2a 270 µg/ml excipient: benzyl alcohol glacial acetic acid polysorbate 80 sodium acetate trihydrate sodium chloride water for injection active: ribavirin 200mg     excipient: ethylcellulose hypromellose as a component of opadry 03a14309 iron oxide red as a component of opadry 03a14309 iron oxide yellow as a component of opadry 03a14309 magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified talc as a component of opadry 03a14309 sodium starch glycolate titanium dioxide as a component of opadry 03a14309 triacetin - pegasys rbv is indicated for the treatment of chronic hepatitis c (chc) in: · non-cirrhotic patients · cirrhotic patients with compensated liver disease

New Zealand - English - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - peginterferon alfa-2a 360 µg/ml; ribavirin 200mg;  ;   - combination - 180µg/0.5ml + 200mg - active: peginterferon alfa-2a 360 µg/ml excipient: benzyl alcohol glacial acetic acid polysorbate 80 sodium acetate trihydrate sodium chloride water for injection active: ribavirin 200mg     excipient: ethylcellulose hypromellose as a component of opadry 03a14309 iron oxide red as a component of opadry 03a14309 iron oxide yellow as a component of opadry 03a14309 magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified talc as a component of opadry 03a14309 sodium starch glycolate titanium dioxide as a component of opadry 03a14309 triacetin - pegasys rbv is indicated for the treatment of chronic hepatitis c (chc) in: · non-cirrhotic patients · cirrhotic patients with compensated liver disease

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - clarithromycin -